- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
A study published this week in The New England Journal of Medicine, found sotrovimab to be effective treatment against severe COVID-19. The drug is a monoclonal antibody treatment that was designed to prevent patients with COVID-19 from progressing to severe disease. Nearly 600 people were studied, and of the study group only 1% developed progression of symptoms. In the control group that did not receive the drug, 7% had hospitalisation or death. None of the participants in the study group were admitted to the ICU, and five from the placebo group required ICU care and mechanical ventilation. Overall an 85% reduction in risk was observed.
Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars
Additional data provided by
English
Japanese
